30Sep 2021
STATIN trial: predictive performance of competing‐risk model in screening for pre‐eclampsia at 35–37 weeks’ gestation

STATIN trial: predictive performance of competing‐risk model in screening for pre‐eclampsia at 35–37 weeks’ gestation

We aimed to examine the predictive performance of the previously reported competing risks model of screening for preeclampsia (PE) at 35‐37 weeks’ gestation by combinations of maternal risk factors, mean arterial pressure (MAP), uterine artery pulsatility index (UtA‐PI), serum placental growth factor (PlGF) and serum soluble fms‐like tyrosine kinase‐1 (sFLT‐1) in the validation dataset derived from the screened population of the STATIN study. The competing risks model provides an effective and reproducible method for third‐trimester prediction of term PE.

  • #gynaecology - ivf

Like

Save

Share